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Abstract
Aims/hypothesis—Type 2 diabetes is a chronic, heterogeneous disease and a major risk factor
for cardiovascular diseases. The underlying mechanisms leading to progression to type 2 diabetes
are not fully understood and genetic tools may help to identify important pathways of glycaemic
deterioration.
Methods—Using prospective data on American Indians from the Strong Heart Family Study, we
identified 373 individuals defined as progressors (diabetes incident cases), 566 individuals with
transitory impaired fasting glucose (IFG) and 1,011 controls (normal fasting glycaemia at all
visits). We estimated the heritability (h2) of the traits and the evidence for association with 16
known variants identified in type 2 diabetes genome-wide association studies.
Results—We noted high h2 for diabetes progression (h2=0.65±0.16, p=2.7×10−6) but little
contribution of genetic factors to transitory IFG (h2=0.09±0.10, p=0.19) for models adjusted for
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multiple risk factors. At least three variants (in WFS1, TSPAN8 and THADA) were nominally
associated with diabetes progression in age- and sex-adjusted analyses with estimates showing the
same direction of effects as reported in the discovery European ancestry studies.
Conclusions/interpretation—Our findings do not exclude these loci for diabetes susceptibility
in American Indians and suggest phenotypic heterogeneity of the IFG trait, which may have
implications for genetic studies when diagnosis is based on a single time-point measure.
Keywords
Heritability; Impaired fasting glucose; Single nucleotide polymorphisms; Type 2 diabetes
Introduction
Type 2 diabetes is a chronic, heterogeneous, complex disease and a major risk factor for
cardiovascular and renal diseases. It is defined by abnormalities of fasting or postprandial
glucose, which result from insulin resistance and pancreatic beta cell dysfunction [1].
Progressive deterioration in beta cell function is associated with beta cell loss due to
multiple factors including apoptosis [2]. In insulin-resistant individuals, such as those with
obesity, beta cell dysfunction precedes type 2 diabetes onset [3, 4]. Recent evidence
suggests that defects in beta cell function occur early in the pathogenesis of type 2 diabetes,
when individuals progress from normal fasting glucose (NFG) to prediabetes stages of
impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) measured using a 2
h OGTT [1, 5, 6]. American Indians have a higher rate of type 2 diabetes compared with
other racial/ethnic populations [7–10]. Studies of Pima Indians have shown that beta cell
dysfunction is a major determinant of progression from normoglycaemia to type 2 diabetes
[6]; impairment in first-phase insulin secretion and a high basal hepatic endogenous glucose
output were observed in prediabetic American Indians who progressed to type 2 diabetes
[6].
IFG and IGT prevalence is approximately 15% and 26%, respectively, in the US adult
population [11, 12], but higher in American Indians [13]. Prediabetes, a known risk factor
for incident type 2 diabetes [8, 9], is phenotypically heterogeneous [14] with only 25–30%
of individuals progressing to type 2 diabetes over 5 years [15]. In the Strong Heart Study
(SHS), for example, 36.6% of American Indians with prediabetes developed type 2 diabetes
at a median follow-up of 7.8 years [13]. Intense lifestyle and/or drug therapy have been
shown to prevent or delay progression to type 2 diabetes in some individuals [16–20]. The
underlying mechanisms leading to progression to type 2 diabetes are not fully elucidated
[21], with a critical barrier being few prospective studies.
Studies suggest a strong genetic component to type 2 diabetes risk (familial aggregation,
high concordance rates in monozygotic twins and increased risk in first-degree relatives of
affected individuals) [22–24]. Over 60 genetic loci have been identified in candidate gene
and genome-wide association (GWA) studies of type 2 diabetes [25–28]. Many of the
identified loci are in or nearby genes affecting pancreatic beta cell development and function
and insulin secretion [25, 29, 30], supporting a role for beta cell dysfunction and insulin
resistance in type 2 diabetes. However, few large-scale genetic studies have addressed the
genetic determinants of the progressive deterioration of glycaemic status and a limited
number of candidate single nucleotide polymorphism (SNP) studies have evaluated
progression to type 2 diabetes [31]. We hypothesise that progression to type 2 diabetes has a
strong genetic component and that common variants in type 2 diabetes loci identified in
European ancestry are also associated with progression to type 2 diabetes in American
Indians. We also sought to identify the genetic contribution to IFG prediabetes subgroups to
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sort out some of the described phenotypic heterogeneity. Here we report the epidemiology
and genetic characterisation of the diabetes progressor trait in American Indians, a
population with high rates of progression to diabetes.
Methods
Study population
The NHLBI-funded Strong Heart Family Study (SHFS) is a collaborative project involving
investigators at the Texas Biomedical Research Institute (formerly the Southwest
Foundation for Biomedical Research), the University of North Carolina, Medstar Health
Research Institute, the University of Oklahoma Health Sciences Center, Missouri Breaks
Industries Research, and Cornell Medical Center. The study has the cooperation of the
Indian Health Service and the tribes in three geographical areas: Arizona, Oklahoma and
North and South Dakota. The SHFS is a large, family-based genetic study of metabolic and
cardiovascular disease risk factors in American Indians and it is a component of the SHS, a
population-based cohort study of diabetes and cardiovascular disease in American Indians.
The SHFS began as a pilot study in 1998, when ～900 members of extended families of the
SHS parent study were examined. Additional family members were recruited and evaluated
in a clinical visit in 2001– 2003. The total sample was 3,798 individuals from 94
multigenerational families (mean family size of 40 individuals, range 5–110), which were
then re-examined in 2006–2009. Extensive and detailed measures of diabetes, insulin
resistance, glycaemic traits and cardiovascular outcomes are available in the SHFS for one
or two follow-up clinical visits.
The SHFS protocols were approved by the Indian Health Services (IHS) Institutional
Review Board, by Institutional Review Boards of all Institutions and by the Indian tribes
[32, 33]. All participants gave informed consent for genetic testing. The study was
conducted according to the principles expressed in the Declaration of Helsinki. This study
includes 2,011 American Indians free of diabetes at baseline visit and with follow-up data in
2006–2009.
Measurements
Baseline sociodemographic, obesity and glycaemic measures and cardiometabolic risk
factors were obtained through interview, physical examination and laboratory measures.
Physical examinations at baseline and follow-up were performed by centrally trained nurses
and medical assistants following standardised protocols. Data collected included height,
weight, body fat, waist and hip circumference and systolic and diastolic blood pressure.
Twelve-hour fasting blood samples were also collected at each visit [32, 33] and stored at
−70°C. Laboratory assays were performed for fasting glucose (measured by enzymatic
methods), HbA1c (measured by HPLC, standardised to the DCCT assay, available at all
visits in the SHFS among individuals without a diagnosis of type 2 diabetes), cholesterol,
and creatinine. All samples were run blinded in a single laboratory and 5% blinded paired
samples were included for quality control (QC). BMI (kg/m2) was calculated from weight
and height. Additional available measures of obesity were total body fat (measured by
bioelectrical impedance) and waist circumference. Hypertension was defined by a blood
pressure of 140/90 mmHg or higher, or use of antihypertensive drugs. Demographic data
(age, sex, education), lifestyle and behaviours (24 h dietary recall, smoking and alcohol
intake), medical history and medications were obtained using standardised questionnaires
[32, 33]. Physical activity was assessed using an Accusplit AE120 pedometer (Accusplit,
San Jose, CA, USA), as previously described [34]. The average number of steps taken per
day was calculated for any person who had data available for 3 or more days of the sampled
week. We used the sex- and centre-specific 75% percentile of physical activity as an
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arbitrary cut-off point for the analyses, because 7,000–8,000 steps/day correspond to
approximately the average daily steps of 30 min of moderate-intensity activity.
Trait definitions: progression to diabetes, non-progression (control) and transitory IFG
Type 2 diabetes, IFG and NFG were defined using the recent ADA criteria, which include
fasting HbA1c values [1, 35]. Briefly, diabetes was defined as a fasting blood glucose (FBG)
of ≥7.0 mmol/l (≥126 mg/dl), self-reported diabetes, use of diabetic medications or an
HbA1c >6.5% (>48 mmol/mol). An FBG level of 6.1–6.9 mmol/l (100–125 mg/dl) or an
HbA1c value of 5.7–6.4% (39–48 mmol/mol) was considered to indicate IFG and an FBG
level of <6.0 mmol/l (<100 mg/dl) and an HbA1c value of <5.7% (<39 mmol/mol) was
considered to indicate NFG. Our definition of type 2 diabetes progressors was adapted from
the description given by Weyer et al for the natural history of insulin secretory dysfunction
and insulin resistance in progression to diabetes in Pima Indians [6]. We defined diabetes
progressors as individuals with new-onset diabetes at follow-up (n=373) and excluded
prevalent diabetes at baseline visit. Individuals with persistent IFG over all visits (n=61)
were included in a separate category. Controls were individuals aged 25 years or older at
baseline visit with NFG at baseline and through all follow-up visits (up to three visits
including baseline). Individuals presenting with new-onset IFG or prospectively changing
from IFG to NFG over the observed period were defined as transitory IFG (as the
progression to diabetes could not be established within available follow-up). Eighty-nine per
cent of individuals with transitory IFG changed from NFG to IFG over 5–10 years of
observation, and the remainder changed from IFG to NFG at follow-up. The median follow-
up time for individuals classified as diabetes progressors, persistent IFG, transitory IFG and
controls were 6.9, 5.2, 5.9 and 5.9 years, respectively, and the minimum follow-up was 3
years for all the groups.
Genotyping and existing markers
SNPs were selected from type 2 diabetes GWA publications of European and Asian ancestry
(available at the genome catalogue up to January 2011) [36] and our analysis was thus
restricted to these loci. SNPs were genotyped using the TaqMan genotyping assays (Life
Technology, Carlsbad, CA, USA) or the multiplex VeraCode technology from Illumina (San
Diego, CA, USA), according to the manufacturers’ protocols. Details of both technologies
are reported elsewhere [37]. Replica samples were included as controls. Extensive standard
QC was applied to genotyped data and included sample call rates (>95%), concordance of
blinded replicates (>98%) and deviation from Hardy–Weinberg equilibrium among founders
(p>0.01). Individuals with more than 10% of missing genotypes (n=64) were excluded.
SNPs that failed genotyping were rs4430796 (HNF1B), rs2074196 (KCNQ1) and rs1326634
(SLC30A8).
Statistical analysis
We estimated heritability (h2), using maximum likelihood variance decomposition methods
[38] and a liability threshold model, in analyses adjusted for age and sex in the overall
sample and within each recruiting centre, separately for diabetes progressors, persistent IFG
and transitory IFG compared with controls. We also tested the effect of clinical and
laboratory risk factors on diabetes progressors, persistent IFG and transitory IFG by further
adjusting for the following covariates: education (12 years or more vs <12 years), smoking
(ever vs never), BMI, HDL-cholesterol, LDL-cholesterol, systolic and diastolic blood
pressures, hypertension treatment, physical activity (75% upper vs lower percentiles) and
using α=0.05 for significance. Models were implemented in SOLAR, which accounts for
family relatedness [38]. The number of relative-pairs overall and within each geographical
region is shown in electronic supplementary materials (ESM) Table 1.
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Association analyses were performed only for traits that showed significant heritability. We
performed centre-stratified analyses and combined the evidence from each centre using
fixed-effect meta-analyses. We used this strategy because of regional differences in allele
frequencies of genetic markers. We assessed associations among diabetes progressors
compared with controls using measured genotype (mixed models to account for family
relatedness) and additive genetic models, adjusted for age and sex. We also provide results
with further adjustments for BMI for main findings. Significance thresholds were
Bonferroni adjusted for the number of independent SNPs (linkage disequilibrium r2<0.5)
used in analyses and p<0.003 (16 SNPs) was considered significant. The between-centre
variance was estimated and we considered evidence for heterogeneity as p<0.05. We also
estimated the trait variability explained by significant variants by comparing liability models
within and without using the SNPs as covariates and using a summary score of all SNPs
based on reported coded allele (range 0–22, the highest having more at-risk alleles).
Results
Risk factor burden in diabetes progressors, transitory IFG and controls
After exclusions, 2,011 SHFS individuals were eligible for analysis of which 373 were
diabetes progressors, 61 had persistent IFG, 566 had transitory IFG and 1,011 were controls.
The cumulative incidence of diabetes progression was 28.5% for individuals recruited from
Arizona, 13.9% for Oklahoma and 15.6% for the Dakotas (Table 1). The mean age for
controls at the last follow-up visit was 47.3 years (SD=13.1), compatible with long-term
normoglycaemia.
Overall, diabetes progressors had higher BMI, percentage of body fat and measures of
central obesity than individuals with transitory IFG and controls, although most individuals
were overweight (BMI>25 kg/m2) or obese (BMI>30 kg/m2) (Table 1). These findings are
consistent with those described in Pima Indians and other ethnic populations [6]. Compared
with controls, individuals progressing to type 2 diabetes and those classified as having
transitory IFG had more cardiometabolic risk factors including higher blood pressure levels
and prevalent hypertension, and lower HDL-cholesterol. These individuals were also less
likely to have undergone 12 years of education. However, controls were more often found to
be current smokers. Transitory IFG risk factor burden was intermediate between diabetes
progressors and controls. Individuals progressing to type 2 diabetes were also less active
than those in the transitory IFG group and controls. Individuals with persistent IFG had
cardiometabolic risk factors more closely resembling diabetes progressors than the other
groups although the sample was small.
Epidemiology of diabetes progressor and IFG
Significant risk factors for diabetes progression in multivariate analyses were high BMI
(p=4.8×10−6), lower HDL-cholesterol (p=5.5×10−9) and living in Arizona (p=5.9×10−3)
compared with the Dakotas. For persistent IFG, the only significant predictor was male sex
(p=0.003). For transitory IFG, male sex (p=7.0×10−3), lower level of education
(p=3.5×10−7), higher BMI (p=2.5×10−4), higher systolic blood pressure (p=7.4×10−3), lower
HDL-cholesterol (p=0.02) and belonging to the Oklahoma centre compared with the
Dakotas (p=2.8×10−5) were significantly associated risk factors. These risk factors
accounted for 15%, 11% and 8% of the phenotypic variability of diabetes progression,
persistent IFG and transitory IFG, respectively, in models adjusted for age, sex, education,
current smoking, BMI, percentage of body fat, systolic and diastolic blood pressure,
hypertension treatment, HDL-cholesterol and LDL-cholesterol).
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Genetic determinants of diabetes progression
We first evaluated the proportion of the phenotypic variance due to genetic effects
(heritability) among diabetes progressors and among individuals with transitory IFG
compared with controls. Heritability is considered to be the single most useful measure of
familial aggregation of disease [39]. In a fully adjusted model accounting for the risk factors
described in Table 1, the overall heritability of diabetes progressor trait was 0.65 (SD=0.16,
p=2.7×10−6) (Fig. 1). Interestingly, the heritability of persistent IFG was 31% and transitory
IFG was 9%, neither of which was significantly greater than zero. We then examined the
association of 16 known GWA type 2 diabetes SNPs in 16 loci with type 2 diabetes
progression. SNPs that passed QC and their minor allele frequencies are shown in Table 2.
All genotyped variants had allele frequencies higher than 1% in American Indians (Table 2).
Association results for SNPs (and their loci) within each centre and in meta-analyses across
all centres are shown in Table 2. Several SNPs were nominally associated with diabetes
progression including SNPs nearby WFS1, TSPAN8, and THADA. There was no evidence
for between-centre heterogeneity of effects for most of the associated variants (Table 2). The
mean at-risk allele scores were 15.1 and 14.8 for individuals developing diabetes and for
controls, respectively. The risk score was not associated with diabetes progression (p=0.20).
Discussion
Among SHFS American Indians, a population with a high rate of obesity and insulin
resistance, we identified subgroups that either progressed to type 2 diabetes or had persistent
or transitory IFG. We confirmed the strong evidence for genetic susceptibility for diabetes
progression in American Indians [40]. Individuals with persistent and transitory IFG had an
intermediate risk factor burden compared with diabetes progressors and normoglycaemic
controls, but the evidence for polygenic genetic effects was weak based on heritability
estimates. The low contribution of genetic factors to transitory IFG may be related to
phenotypic heterogeneity, previously described in longitudinal glycaemic studies [14].
Studies have shown that only one in four individuals with prediabetes will develop diabetes
[15]. Obesity-related environmental factors, such as diet and physical activity, may
contribute to early abnormalities of fasting glucose in a subset of individuals. Future work
using longitudinal glycaemic measures may provide a better characterisation of prediabetes
subgroups for which the contribution of genetic and environmental factors may vary. The
sample size for persistent IFG was small and further studies are needed to confirm the
findings for this subgroup. These findings may have implications in the genetic research of
prediabetes when using a single time-point glycaemic measure and in the implementation of
preventive measures for glycaemic deterioration in populations with a high burden of insulin
resistance and cardiometabolic risk factors, given the global obesity epidemic.
We also explored the evidence for generalisation of associations of common genetic
variants, identified in GWAs using type 2 diabetes case-control designs, with diabetes
progression in American Indians. SNPs in the WFS1, TSPAN8 and THADA loci showed
nominal associations in meta-analysis of all recruiting centres. Importantly, although there
were regional differences in allele frequencies of genetic markers, we found no evidence for
between-centre heterogeneity of genetic effects for these common variants. SNPs showed
similar direction of effect as those described in individuals of European ancestry [41] but
allele frequencies were lower in American Indians compared with European ancestry
populations (ESM Table 2). Effects sizes were larger for associations in American Indians
for diabetes progression compared with reported European population-based estimates in
type 2 diabetes case-control studies. For example, the OR for each C allele copy of
rs7961581 (TSPAN8) was 1.39 in American Indians compared with 1.09 in European
ancestry meta-analysis [41]. Interestingly, TCF7L2 SNPs identified through a
comprehensive genotyping of the locus were previously shown to not associate with
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diabetes in Pima Indians [42]. In our study, we found nominal associations with diabetes
progression only in the Arizona centre (Table 2) but this SNP estimate also showed strong
evidence for between-study heterogeneity (p for heterogeneity=0.002). We do not know the
underlying genetic architecture of diabetes in American Indians and how well the available
SNPs capture the functional variants in these loci.
The WFS1 variant has been prospectively associated with development of type 2 diabetes
among individuals of European ancestry [43]. For remaining loci, differences in linkage
disequilibrium of the genotyped SNP with the ‘causal’ variant(s) between American Indians
and individuals of European ancestry, the population used in the discovery, may account for
some of the negative findings. Because only the published SNP was available in these
regions, we cannot rule out presence of additional variants in these and in other loci
accounting for type 2 diabetes risk. It is possible that true associations may have been
overlooked due to low power. We estimated that we only had 80% power for large effect
sizes for analyses of diabetes progression, persistent IFG and transitory IFG compared with
controls (ESM Table 3). The analyses were also limited to type 2 diabetes loci with
validated GWAS variants published up until 2011, when the SNPs were selected.
Our findings do not exclude these loci as being important to diabetes in American Indians.
Findings from other ethnic populations [44, 45] suggest that type 2 diabetes loci may be
relevant to diverse ancestral populations. American Indians have a large burden of obesity,
insulin resistance and early-onset type 2 diabetes, and studies of this population have the
potential to uncover mechanisms related to progression to diabetes. However, a limited
number of GWA studies have been performed in American Indians [46, 47].
In summary, using longitudinal data to define type 2 diabetes progression in American
Indians who have previously been shown to have high burden of obesity, insulin resistance
and type 2 diabetes, we showed evidence for a high genetic susceptibility to diabetes
progression, and nominal replication of some SNPs in known type 2 diabetes loci to
American Indians. Importantly, there was little evidence for contribution of genetic factors
to transitory IFG, which could have public health implications when promoting healthy
lifestyle [48, 49]. This study expands the knowledge on the genetics of progressive
deterioration of glycaemic status in individuals at high risk of type 2 diabetes. Further work,
including fine-mapping and/or sequencing of these regions, will be needed to better
characterise the role of these genes in the susceptibility to diabetes in American Indians.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Heritability of diabetes (n=373), persistent IFG (n=61) and transitory IFG (n=566).
Estimates and SD are shown for polygenic models adjusted for age and sex using
individuals with normal glycaemia as controls (n=1,011). Note that only diabetes had
significant heritability and numbers were small for estimate heritability among individuals
with persistent IFG
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